PFA-based Bi-atrial Maze-like Catheter Ablation for PeAF

NCT06952023 · tracked via the Priya Life Science China tracker

Sponsor

The First Affiliated Hospital of Dalian Medical University

Phase

Not applicable

Started

2025-06

Last updated

2025-04-30

Condition(s) studied

Atrial FibrillationPersistent Atrial Fibrillation

Investigational drug(s) / intervention(s)

Modified Maze ablation with PFAPVI only with PFA

Modified Maze ablation with PFA: Modified Maze ablation with PFA

PVI only with PFA: PVI only with PFA

Study summary

In radiofrequency (RF) ablation of persistent atrial fibrillation (PeAF), the additional linear ablation beyond pulmonary vein isolation (PVI) does not yield an reduce atrial arrhythmias recurrences.The goal of this clinical trial is to evaluate the efficiency of pulsed filed (PF) energy-based bi-atrial modified Maze ablation vs PF energy-based PVI of PeAF.

The main questions it aims to answer are:

Does PF energy effectively perform linear ablation in the left atrium? Does PFA-based bi-atrial modified Maze ablation significantly improve the success rate of PeAF ablation compared with PFA-based PVI?

Patients with PeAF who meet the criteria and undergo catheter ablation will be randomly assigned to the study group (PF-based bi-atrial modified Maze ablation group) and control group (PF-based PVI only) in a 1:1 ratio. All patients will received a 7-d Holter at 3-,6-,9-,12-month after the ablation. The primary endpoint is the freedom from documented atrial arrhythmia (AF/AFL/AT lasting for over 30 seconds) recurrence monitored by ECG, 7-day ambulatory ECG, or equivalent cardiac monitoring from 4th to 12th month after the procedure without taking I/III AADs.

Eligibility

Sex

ALL

Min age

18 Years

Max age

75 Years

Healthy volunteers

Inclusion Criteria: * Patients diagnosed with symptomatic PeAF at 18-75 years old who are eligible for the PFA procedure, and have any the following documentation, within 180 days of randomization of either: i. A 24-hour continuous ECG recording (from any regulatory cleared rhythm monitoring device) confirming continuous AF, OR ii. Two ECGs (from any regulatory cleared rhythm monitoring device) showing continuous AF taken at least 7 days，OR iii. physician note of persistent continuous AF for \> 7 days * The duration of AF lasting ≥ 1 year Exclusion Criteria: * PaAF or PeAF with duration \< 1 year * has received catheter ablation procedure for AF or atrial septal defect repair before enrollment * left atrial diameter ≥55 mm or thrombosis in the left atrium * eGFR\<30mL/min/1.73m2 * a history of cerebrovascular disease within the last three months (including stroke and transient ischemic attack) * acute or severe systemic infection * refused to participate in this trial; or those who have participated in other clinical drug trials within 3 months prior to enrollment * congenital heart disease, thyroid dysfunction, severe hepatic insufficiency (Child-Pugh classification B-C), severe coagulation dysfunction (international normalized ratio \> 1.5 or partial activated prothrombin time prolonged by ≥ 10 seconds, or plasma prothrombin time prolonged by ≥ 3 seconds, or fibrinogen ≤ 1.5 g/L), or active bleeding * pregnant women, breastfeeding women or women who plan to become pregnant during the study period, those who have a positive pregnancy test result during the screening period * life expectancy \< 12 months

Primary outcome measure(s)

Freedom from atrial tachycardia during blanking period to Month 12 — during blanking period to Month 12
freedom of occurrence ≥ 30 sec of Atrial Fibrillation (AF), Atrial Flutter (AFL), atrial Tachycardia (AT); or any electrical cardioversion or re-ablation for AF, AFL, or AT; or any Class I or III AAD use

Trial sites (3)

Facility	City	Region
Jiangsu Provincial Hospital	Nanjing	Jiangsu
First Affiliated Hospital of Dalian Medical University	Dalian	Liaoning
The Affiliated Hospital Of Medical School Of Ningbo University	Ningbo	Zhejiang

More The First Affiliated Hospital of Dalian Medical University trials in China

Use of Pegmolesatide in Renal Anemia: Efficacy and Safety of Switching to Pegmolesatide in Non-dialysis CKD Patients Treated With rhuEPO or HIF-PHI Recruiting

DPA-714 and FDG PET/MRI in Depression Recruiting

an Observational Study Evaluting the Effectiveness and Safety of DKutting LL Noval Scoring Balloon Angioplasty for Vessel Preparation Facilitated by IVUS on the Lower Limb Ischemia Patients With Calcified Lesions Enrolling by invitation

Benzodiazepine Impact on Cognitive Function: fNIRs and PET/MRI Study Recruiting

Deep Sedation in Catheter Ablation of Atrial Fibrillation Starting soon

Other trials for the same condition

A Study of Varipulse Catheter in Participants With Paroxysmal Atrial Fibrillation Under Optimized Sedation Recruiting

Atrial Fibrillation Patients Treated With Catheter Ablation Recruiting

Prospective Study on the Effectiveness and Safety of Bi-polar Pulse-field Tip-catheter Ablation for Atrial Fibrillation in China（POTENTIAL-AF） Starting soon

The Effect of Low-Level Tragus Stimulation on Inflammation and Early Recurrence After Pulsed Field Ablation: A Randomized Controlled Study Active, not recruiting

PVI Alone vs PVI and Linear Ablation for Persistent Atrial Fibrillation (PROMPT AF II) Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06952023 on ClinicalTrials.gov ↗ ← All trials in China